Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage

Among the various histopathological patterns of drug-induced interstitial lung disease (DILD), diffuse alveolar damage (DAD) is associated with poor prognosis. However, there is no reliable biomarker for its accurate diagnosis. Here, we show stratifin/14-3-3σ (SFN) as a biomarker candidate found in...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2022-10, Vol.13 (1), p.5854-5854, Article 5854
Main Authors: Arakawa, Noriaki, Ushiki, Atsuhito, Abe, Mitsuhiro, Matsuyama, Shinichiro, Saito, Yoshinobu, Kashiwada, Takeru, Horimasu, Yasushi, Gemma, Akihiko, Tatsumi, Koichiro, Hattori, Noboru, Tsushima, Kenji, Miyashita, Keiko, Saito, Kosuke, Nakamura, Ryosuke, Toyoda, Takeshi, Ogawa, Kumiko, Sato, Motonobu, Takamatsu, Kazuhiko, Mori, Kazuhiko, Nishiya, Takayoshi, Izumi, Takashi, Ohno, Yasuo, Saito, Yoshiro, Hanaoka, Masayuki
Format: Article
Language:English
Subjects:
38/47
631/45/612/1248
692/53/2421
692/699/1785/3193
82/1
82/51
96/2
Alveoli
Apoptosis
Biomarkers
Bronchus
Damage
Diagnosis
Epithelial cells
Epithelium
Humanities and Social Sciences
Lavage
Lung diseases
multidisciplinary
Prognosis
Proteomics
Science
Science (multidisciplinary)
Stratifin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among the various histopathological patterns of drug-induced interstitial lung disease (DILD), diffuse alveolar damage (DAD) is associated with poor prognosis. However, there is no reliable biomarker for its accurate diagnosis. Here, we show stratifin/14-3-3σ (SFN) as a biomarker candidate found in a proteomic analysis. The study includes two independent cohorts (including totally 26 patients with DAD) and controls (total 432 samples). SFN is specifically elevated in DILD patients with DAD, and is superior to the known biomarkers, KL-6 and SP-D, in discrimination of DILD patients with DAD from patients with other DILD patterns or other lung diseases. SFN is also increased in serum from patients with idiopathic DAD, and in lung tissues and bronchoalveolar lavage fluid of patients with DAD. In vitro analysis using cultured lung epithelial cells suggests that extracellular release of SFN occurs via p53-dependent apoptosis. We conclude that serum SFN is a promising biomarker for DAD diagnosis. No reliable serum biomarker for diffuse alveolar damage, a poor prognosis subtype of drug-induced interstitial lung disease, is currently available. Here, the authors show stratifin/14-3-3σ in serum is a promising biomarker for diagnosis of this type of disease.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-022-33160-9